Tuesday, November 7, 2017
- 9:00AM-11:00AM
-
Abstract Number: 2668
Responsiveness of University of California Los Angeles Scleroderma Clinical Trial Consortium (GIT2.0) and Intestinal Visual Analogue Scale to Change in Systemic Sclerosis Patients
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III- 9:00AM-11:00AM
-
Abstract Number: 2478
Retention on Adalimumab, Etanercept, Golimumab and Infliximab in Two Eras – Experience of Patients with Rheumatoid Arthritis from a Real-World Database RHUMADATA®
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2357
Retinal Vessel Morphological Associations with Systemic Inflammation and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2422
Rheumatoid Arthritis (RA) Synovial Fluid Treg Cells Secrete IL-17 and at the Same Time Are Potent Suppressors of Tresp Cell Proliferation, TNF-α and Interferon γ Production
Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster III- 9:00AM-11:00AM
-
Abstract Number: 2399
Rheumatoid Arthritis Have Lower Glomerular Filtration Rate Compared to Healthy Population: Role of Inflammation
Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2401
Rheumatoid Arthritis with Kidney Dysfunction Contributes to Higher Risk of Cardiovascular Disease Development
Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2741
Rheumatoid Factor (RF) Levels Remain Persistently Elevated 24 Weeks after Interferon (INF) Free Direct Antiviral Agents (DAA) Therapy in the Majority of RF+ HCV Infected Persons
Vasculitis Poster III: Other Vasculitis Syndromes- 9:00AM-11:00AM
-
Abstract Number: 2119
Rheumatological Immune Related Adverse Events in Malignancy Patients Treated with Anti-Programmed Cell Death (PD) 1 Antibodies
Miscellaneous Rheumatic and Inflammatory Diseases Poster II- 9:00AM-11:00AM
-
Abstract Number: 2498
Rheumatologists Use Different Cut-Offs for Disease Activity in Real Life – the Experience with Golimumab in Ankylosing Spondylitis- Subanalysis from a Non-Interventional German Study
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2036
Rheumatologists’ Compliance with Screening for Viral Hepatitis B and C Prior to Initiation of Methotrexate Treatment Needs Quality Improvement
Measures and Measurement of Healthcare Quality Poster II- 9:00AM-11:00AM
-
Abstract Number: 2309
Risk Factors for Arthritis and the Development of Comorbid Cardiovascular and Metabolic Disease in Children with Psoriasis
Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1961
Risk Factors for Low Muscle MASS in Community-Dwelling Older Women: A Population-Based Prospective Cohort Study in Brazil. the São Paulo Ageing & Health Study
Epidemiology and Public Health Poster III: Rheumatic Disease Risk and Outcomes- 9:00AM-11:00AM
-
Abstract Number: 2188
Risk of Disability in Underweight Persons with or at Increased Risk of Knee Osteoarthritis